Global Ventilator Associated Pneumonia (VAP) Pipeline Guide: Companies Involved in Therapeutics Development

DUBLIN, May 12, 2020 /PRNewswire/ -- The "Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2020" drug pipelines has been added to's offering.

The "Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2020" provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

This pipeline guide provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews key players involved in therapeutic development for VAP and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 5, 9, 1, 7, 2 and 1 respectively.

The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Ventilator Associated Pneumonia (VAP).
    --  The pipeline guide reviews pipeline therapeutics for VAP by companies
        and universities/research institutes based on information derived from
        company and industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in VAP therapeutics
        and enlists all their major and minor projects.
    --  The pipeline guide evaluates VAP therapeutics based on mechanism of
        action (MoA), drug target, route of administration (RoA) and molecule
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Ventilator Associated Pneumonia (VAP).

Reasons to buy

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Ventilator Associated Pneumonia (VAP).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding VAP
        pipeline depth and focus of Indication therapeutics.
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and Scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Key Topics Covered:

    --  Ventilator Associated Pneumonia (VAP) - Overview
    --  Ventilator Associated Pneumonia (VAP) - Therapeutics Development
    --  Pipeline Overview
    --  Pipeline by Companies
    --  Products under Development by Companies
    --  Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment
    --  Assessment by Target
    --  Assessment by Mechanism of Action
    --  Assessment by Route of Administration
    --  Assessment by Molecule Type
    --  Ventilator Associated Pneumonia (VAP) - Companies Involved in
        Therapeutics Development
    --  Ventilator Associated Pneumonia (VAP) - Drug Profiles
    --  (avibactam + aztreonam) - Drug Profile
    --  (avibactam sodium + ceftazidime) - Drug Profile
    --  (cefepime + taniborbactam hydrochloride) - Drug Profile
    --  (cefepime + tazobactam sodium) - Drug Profile
    --  Ventilator Associated Pneumonia (VAP) - Dormant Projects
    --  Ventilator Associated Pneumonia (VAP) - Discontinued Products
    --  Ventilator Associated Pneumonia (VAP) - Product Development Milestones
    --  Featured News & Press Releases
    --  Appendix

Companies Mentioned

    --  Aridis Pharmaceuticals Inc
    --  AstraZeneca Plc
    --  Bioversys AG
    --  Cumberland Pharmaceuticals Inc
    --  CytaCoat AB
    --  Destiny Pharma Plc
    --  Dong-A Socio Holdings Co Ltd
    --  EnBiotix Inc
    --  Evaxion Biotech ApS
    --  Hypo-Stream Ltd
    --  Meiji Seika Pharma Co Ltd
    --  Merck & Co Inc
    --  Motif Bio Plc
    --  Nabriva Therapeutics Plc
    --  Nosopharm SAS
    --  Peptineo
    --  Polyphor AG
    --  Shionogi & Co Ltd
    --  Spero Therapeutics Inc
    --  Tetraphase Pharmaceuticals Inc
    --  TGV-Inhalonix Inc
    --  VenatoRx Pharmaceuticals Inc
    --  Wockhardt Ltd

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets